Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
48 hedge funds and large institutions have $42.4M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 5 closing their positions.
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2% more funds holding
Funds holding: 47 → 48 (+1)
56% less capital invested
Capital invested by funds: $97.4M → $42.4M (-$55M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$615K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$303K |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$189K |
| 4 |
Two Sigma Investments
New York
|
+$185K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$157K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Ion Asset Management
Herzliya,
Israel
|
-$2.24M |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$845K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$742K |
| 4 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
-$736K |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$388K |
ELOX Hedge Fund Activity: Q3 2019 in Review
48 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q3 2019, worth a combined $42.4M — down 56% from $97.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ELOX positions and 5 closed out — a net gain of 1 holder — while 23 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $615K. The largest seller was Ion Asset Management, exiting entirely with an estimated $2.24M sold.
- 48 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q3 2019, up from 47 in Q2 2019.
- Funds reported $42.4M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q3 2019, down 56% quarter-over-quarter.
- 6 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q3 2019 and 5 closed out, a net change of +1 holder.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q3 2019 was BlackRock, an estimated $615K added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q3 2019 was Ion Asset Management, an estimated $2.24M sold.
Based on aggregated 13F filings for Q3 2019.